TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02252536
Drug: gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
Study: NCT00789750
Drug: Colesevelam
Normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam 625 mg tablets
Study: NCT00789750
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg or 45 mg pioglitazone therapy
Study: NCT00962390
Drug: S-equol
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg S-equol 50mg S-equol, \& 150mg S-equol
Study: NCT00686270
Drug: apricitabine
Normalized name: Apricitabine
DrugBank: Apricitabine (DB12855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
Study: NCT04503551
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will be administered as per the schedule described in individual arm.
Study: NCT04503551
Drug: Intravitreal Ranibizumab 0.5 mg Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will be administered as per the schedule described in individual arm.
Study: NCT00422773
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
Study: NCT00161330
Drug: oral amoxicilline/clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00161330
Drug: iv ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03199339
Drug: TBA-7371
Normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Study: NCT00088998
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00184574
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00184574
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02633852
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01271790
Drug: Tegobuvir (GS-9190)
Normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegobuvir (GS-9190) capsule, 30 mg BID
Study: NCT01271790
Drug: GS-9451
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 tablet, 200 mg once daily (QD)
Study: NCT01271790
Drug: GS-9451
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 tablet, 200 mg QD
Study: NCT00720473
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine with dosage range from 25 mg to 200 mg per day.
Study: NCT01271790
Drug: Tegobuvir placebo
DrugBank: Tegobuvir (DB11852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching Tegobuvir (GS-9190) capsule BID
Study: NCT01856283
Drug: Nilotinib 300mg BID
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib
Study: NCT03538522
Drug: N-831(Traneurocin) 10 mg QD
Normalized name: tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
Study: NCT03538522
Drug: NA-831 (Traneurocin) 20 mg QD
Normalized name: fosinopril sodium 20 MG
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
Study: NCT03538522
Drug: NA-831 (Traneurocin) 40 mg QD
Normalized name: fosinopril sodium 40 MG
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
Study: NCT03319901
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death.
Study: NCT00670267
Drug: nadolol
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
Study: NCT01495169
Drug: iloperidone (oral tablet)
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
Study: NCT00078312
Drug: CEP-10953 (Armodafinil)
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Armodafinil (po) 100 to 250 mg/day up to 12 months
Study: NCT00006096
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01339858
Drug: N-Acetyl Cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
Study: NCT00063596
Drug: Vitamin A supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03202186
Drug: Progesterone oral capsule
Normalized name: progesterone Oral Capsule
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capsule treatment
Study: NCT04099771
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine infusion
Study: NCT02820935
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02820935
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02820935
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01178112
Drug: Trientine
Normalized name: Trientine
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
Study: NCT01178112
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
Study: NCT01198379
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 100 mg qd for 3 years
Study: NCT00413478
Drug: 5-Azacytidine
Normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
Study: NCT01178112
Drug: Carboplatin MTD
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maximum tolerated dose found in MTD Dose Escalation Group
Study: NCT02748616
Drug: Ursodiol
Normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
Study: NCT02039817
Drug: IDN-6556
Normalized name: IDN-7314
DrugBank: IDN-7314 (DB18073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00106379
Drug: Truvada (tenofovir DF + emtricitabine)
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00106379
Drug: Emtriva (emtricitabine)
Normalized name: emtricitabine Oral Capsule [Emtriva]
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00106379
Drug: Viread (tenofovir DF)
Normalized name: tenofovir disoproxil Oral Tablet [Viread]
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01640093
Drug: Abiraterone acetate, 250 mg (uncoated, current commercial tablet)
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
Study: NCT01640093
Drug: Abiraterone acetate, 500 mg (coated, reformulated tablet)
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
Study: NCT03332797
Drug: GDC-9545
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT03332797
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT03964727
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT01889199
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 125 mg orally each 28 day cycle for 6 cycles
Study: NCT00782275
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00782275
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00068406
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01296152
Drug: depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
Study: NCT02018042
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug.
Study: NCT02353299
Drug: Silenor 6 mg
Normalized name: Silenor 6 MG Oral Tablet
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silenor 6 mg single nighttime dose.
Study: NCT02353299
Drug: zolpidem 10 mg
Normalized name: zolpidem 10 mg oral tablet
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem 10 mg single nighttime dose
Study: NCT01640093
Drug: Abiraterone acetate, 250 mg (coated, reformulated tablet)
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
Study: NCT01640093
Drug: Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
Study: NCT01778179
Drug: Tri-luma
Normalized name: Tri-Luma
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.
Study: NCT03823378
Drug: Elsubrutinib
Normalized name: Elsubrutinib
DrugBank: Elsubrutinib (DB18850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elsubrutinib capsule will be administered orally.
Study: NCT03823378
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib tablet will be administered orally.
Study: NCT03823378
Drug: Placebo for elsubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for elsubrutinib will be administered orally.
Study: NCT03823378
Drug: Placebo for upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib placebo tablet will be administered orally.
Study: NCT00058539
Drug: rhuMAb 2C4 (pertuzumab)
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01178996
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks
Study: NCT01408056
Drug: Timolol 0.5% Gel Forming Solution (GFS)
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day
Study: NCT01408056
Drug: Mupirocin 2% Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application twice per day for 60 days
Study: NCT03298542
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
Study: NCT01653028
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02960997
Drug: Sirolimus, 2%
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02797067
Drug: Glycerin Suppository
Normalized name: Leader Pediatric Glycerin Suppository
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30min before ESWL
Study: NCT03559920
Drug: Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
Study: NCT03559920
Drug: Sedate using propofol.
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
Study: NCT00002951
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04739865
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label
Study: NCT02656615
Drug: abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
Study: NCT02367066
Drug: AR-C165395XX
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of AR-C165395XX (tablets)
Study: NCT02281929
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
Study: NCT01182766
Drug: Topiramate with brief behavioral enhancement therapy
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
Study: NCT01221727
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
Study: NCT01221727
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive two oral dose administrations of midazolam.
Study: NCT03846167
Drug: Imaging Drug FluorThanatrace (FTT)
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
Study: NCT00909233
Drug: Vardenafil, (Levitra, BAY38-9456)
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients under daily life treatment receiving Levitra according to local drug information.
Study: NCT03675776
Drug: Rapastinel
Normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration).
Study: NCT03684642
Drug: Efpeglenatide
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection; Route of administration: SC
Study: NCT03684642
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: solution for injection; Route of administration: SC
Study: NCT03684642
Drug: Background therapy Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
Study: NCT02952937
Drug: GLA5PR GLARS-NF3 tablet 300mg
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A new formulation(3rd.) of Pregabalin CR tablet
Study: NCT01082380
Drug: PF-02341066
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
Study: NCT02856893
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib 60 or 40 mg daily until progression
Study: NCT02856893
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250mg daily until progression
Study: NCT00034749
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03332511
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300mg twice-daily
Study: NCT00001965
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03103061
Drug: Lexiscan
Normalized name: Lexiscan
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coronary vasodilator
Study: NCT02270437
Drug: ropivacaine, fentanyl, adrenaline
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
Study: NCT01981369
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous sedation with dexmedetomidine
Study: NCT01981369
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sedation with propofol
Study: NCT00293488
Drug: polyamine analogue PG11047
Normalized name: POLOXAMINE 1304
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02744937
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin is continued by its regular dosing